Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,378.0
16.9 (0.50%)

 

  • STI Straits Times Index
    3,378.0
    16.9 (0.50%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,658.2
    9.3 (0.56%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,765.4
    303.7 (1.07%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,924.2
    23.0 (0.79%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    21,467.0
    420.8 (2.00%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,456.5
    53.2 (0.83%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,094.4
    27.8 (1.35%)
    Index delayed 20 minutes
  • XAO XAO
    6,786.2
    50.8 (0.75%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 951.8M
  • Value: 1,059.6M
  • Rise: 198
  • Fall: 120
  • Unch: 520

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Libra0.052+0.025
QT Vascular0.006+0.002
Sino Grandness0.050+0.004
SunMoonFood^0.063+0.005
Koh Eco0.058+0.001
G Invacom^0.137+0.005
Genting Sing0.920-
Sen Yue0.038-
Golden Agri-Res0.300-
TEE Intl0.102+0.001

World Indices

World Indices
Name Last Change
Nasdaq 8,146.5 -60.8
HSI 28,765.4 +303.7
HSCEI 10,909.4 +124.9
Jakarta 6,456.5 +53.2
Nikkei 225 21,467.0 +420.8
SSE Comp 2,924.2 +23.0
Shanghai A 3,062.8 +24.1
Shanghai B 290.0 +1.3
ShenZhen A 1,631.7 +12.2
ShenZhen B 972.3 +3.6
Taiwan W 10,873.2 +73.9
PSE Comp 0.0
KOSPI 2,094.4 +27.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

NGM BIOPHARMACEUTICALS INC NGM BIOPHARMACEUTICALS INC
Updated on 19 Jul 2019 (End of trading day)
Last (USD): 14.030 Change: -0.080 High: 14.320 Remarks: -
Change (%): -0.57 Low: 13.920
Open 14.130 Yesterday's Close 14.11
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 28,377 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.00747 Trailing EPS (USD) e -0.00747 NAV (USD) b -1.8051
PE a - Trailing PE f - Price / NAV b -7.7724
Dividend (USD) d - Cash In Hand (USD) g 0.7166 Issued & Paid-up Shares c 66,022,000
Dividend Yield (%) d - Price / Cash In Hand g 19.579 Treasury Shares h -
Beta - 75 Daysi -0.043 R-Squared - 75 Days(%)i 0.02 Market Cap (M) 926.289
Beta - 500 Daysi -0.044 R-Squared - 500 Days (%)i 0.02 Enterprise Value (M) 1,027.922
Piotroski F Score 3 Exchange Code NGM Par Value ( $ ) n.a.
52 Weeks Volatility (%) n.a. Free Float (%) 26.6
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 20 May 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 27 Mar 2019.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference NGM BIOPHARMACEUTICALS INC NASDAQ 926.289 - - -7.7724 -
Industry Biotechnology NASDAQ 2,292.877 130.889 102.010 5.4570 0.777
Local Peer AMGEN INC NASDAQ 108,806.483 12.962 13.474 10.0449 3.055
Local Peer GILEAD SCIENCES INC NASDAQ 82,702.262 15.161 14.036 3.7676 3.534
Local Peer CELGENE CORP NASDAQ 63,614.452 15.723 13.407 7.7911 -
Local Peer VERTEX PHARMACEUTICAL NASDAQ 44,598.350 21.274 20.697 9.4422 -
Local Peer BIOGEN INC NASDAQ 44,841.634 10.121 9.609 3.2424 -
Local Peer ILLUMINA INC NASDAQ 43,100.400 52.180 50.647 10.8157 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,684.289 13.371 13.464 3.4606 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 27,087.830 349.072 65.052 2.7907 -
Local Peer INCYTE CORPORATION NASDAQ 17,270.917 157.736 68.279 8.2812 -
Local Peer EXACT SCIENCES CORP NASDAQ 14,835.488 - - 19.0948 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 14,606.821 - - 4.9740 -
Local Peer SEATTLE GENETICS INC NASDAQ 12,140.320 - - 9.5455 -
Other Local Peers SAREPTA THERAPEUTICS INC (NASDAQ), ARRAY BIOPHARMA INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), MODERNA INC (NASDAQ), REPLIGEN CORP (NASDAQ), TILRAY INC (NASDAQ), FIBROGEN INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ACCELERON PHARMA (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), INSMED INC (NASDAQ), NATERA INC (NASDAQ), REGENXBIO INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ANAPTYSBIO INC (NASDAQ), VERACYTE INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), OPKO HEALTH INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), INTREXON CORP (NASDAQ), EDITAS MEDICINE INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), CORTEXYME INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), RADIUS HEALTH INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), RETROPHIN INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ARVINAS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), MACROGENICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), TG THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), VANDA PHARMACE INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), PERSONALIS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), SYNTHORX INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), TRANSLATE BIO INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), DERMIRA INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), PROTHENA CORP PLC (NASDAQ), NEXTCURE INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), RESTORBIO INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), MERUS B V (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), IMMUNOGEN INC (NASDAQ), AGENUS INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), XBIOTECH INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), KAMADA (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), GERON CORP (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), SYNLOGIC INC (NASDAQ), ATHERSYS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), COMPUGEN (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), MANNKIND CORPORATION (NASDAQ), CHIASMA INC (NASDAQ), AFFIMED N V (NASDAQ), AXCELLA HEALTH INC (NASDAQ), CHIMERIX INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), ARDELYX INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), IMV INC (NASDAQ), TOCAGEN INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), SESEN BIO INC (NASDAQ), NANTKWEST INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ADURO BIOTECH INC (NASDAQ), VERASTEM INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), NOVAVAX INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), INMUNE BIO INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), EQUILLIUM INC (NASDAQ), TREVENA INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), SAVARA INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), INFLARX N V (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), VERMILLION INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), ORGENESIS INC (NASDAQ), CURIS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), COHBAR INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), ARAVIVE INC (NASDAQ), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), AQUINOX PHARMACEUTICALS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), VACCINEX INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), ZAFGEN INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), EVOGENE LTD (NASDAQ), CONTRAFECT CORP (NASDAQ), SENESTECH INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), BIONANO GENOMICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), SOLIGENIX INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), BIOCEPT INC (NASDAQ), HISTOGENICS CORP (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), PRECIPIO INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), VICAL INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), OHR PHARMACEUTICAL INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ATYR PHARMA INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), TROVAGENE INC (NASDAQ), VAXART INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADR EA REPR 150 ORD(POST SPLIT) (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADR EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ADVAXIS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), NEURALSTEM INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), OPGEN INC (NASDAQ), CYTORI THERAPEUTICS INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH (NASDAQ)
Global Peer AMGEN-T HKEx 609,936.000 9.271 9.631 7.1731 4.272
Global Peer CSL ASX 101,856.584 45.649 41.810 14.7785 1.014
Global Peer AGILENT TECHNOLOGIES INC NYSE 21,708.719 68.699 19.435 4.2359 0.873
Global Peer SINO BIOPHARM HKEx 112,772.358 10.525 10.803 3.2534 0.816
Global Peer WUXI BIO HKEx 101,735.436 136.210 136.209 11.1604 -
Global Peer BEIGENE HKEx 58,192.327 - - 4.6079 -
Global Peer 3SBIO HKEx 34,416.432 22.751 22.751 3.5034 -
Global Peer Lonza SGX 5,937.453 7.663 7.663 0.6889 4.766
Global Peer GENSCRIPT BIO HKEx 34,034.889 204.675 204.683 9.0819 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,269.310 36.193 54.434 2.2980 -
Other Global Peers HAOHAI BIOTEC (HKEx), FRONTAGE (HKEx), VIVA BIOTECH (HKEx), ASCLETIS-B (HKEx), MYOVANT SCIENCES LTD (NYSE), POLYNOVO LIMITED (ASX), AVITA MEDICAL LTD (ASX), CKLIFE SCIENCES (HKEx), ESSEX BIO-TECH (HKEx), MESOBLAST LTD (ASX), NEXT SCIENCE LTD (ASX), LEE'S PHARM (HKEx), ARCUS BIOSCIENCES INC (NYSE), STARPHARMA HOLDINGS LIMITED (ASX), KADMON HLDGS INC (NYSE), TELIX PHARMACEUTIC (ASX), DPHARMA (Bursa), 22ND CENTURY GROUP INC (NYSE American), STANDARD DIVERSIFIED INC (NYSE American), ENZO BIOCHEM INC (NYSE), PALATIN TECHNOLOGIES INC (NYSE American), PFENEX INC (NYSE American), BBI LIFE SCI (HKEx), BIOTIME INC (NYSE American), HEMISPHERX BIOPHARMA INC (NYSE American), UNI-BIO GROUP (HKEx), CYNATA THERAPEUTICS LTD (ASX), NEUREN PHARMACEUTICALS LTD (ASX), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), PORT (SET), RESAPP HEALTH LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), IBIO INC (NYSE American), CEL-SCI CORP (NYSE American), CT ENTERPRISE (HKEx), REGENT PACIFIC (HKEx), IMMUTEP LTD (ASX), PHYLOGICA LIMITED (ASX), ORTHOCELL LIMITED (ASX), IMUGENE LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), INVEX THERAPEUTICS LTD NPV (ASX), ZELDA THERAPEUTICS LTD (ASX), RHINOMED LIMITED (ASX), BIOTRON (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), EXTRAWELL PHAR (HKEx), BIOSINO BIO-TEC (HKEx), MEMPHASYS LTD (ASX), ONCOSIL MEDICAL LIMITED (ASX), ORAGENICS INC (NYSE American), ISORAY INC (NYSE American), ADALTA LTD (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), ACTINIUM PHARMACEUTICALS INC (NYSE American), PATRYS LIMITED (ASX), KAZIA THERAPEUTICS LIMITED (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), ALTERITY THERAPEUTICS LIMITED (ASX), IMMURON LIMITED (ASX), BIONOMICS LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), NANOVIRICIDES INC (NYSE American), ANTEO DIAGNOSTICS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), GENETIC TECHNOLOGIES (ASX), REGENEUS LTD (ASX), CELLMID LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), Suntar Eco-City^ (SGX), HOLISTA COLLTECH LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), BENITEC BIOPHARMA LTD (ASX), BIOXYNE LIMITED (ASX), QT Vascular (SGX), ACTINOGEN MEDICAL LTD (ASX), HAO WEN HLDGS (HKEx), LIVING CELL TECHNOLOGIES (ASX), MGRC (Bursa), MEGASUN (Bursa), CCP TECHNOLOGIES LTD (ASX), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NOVITA HEALTHCARE LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), MEDIBIO LIMITED (ASX), BPH ENERGY LIMITED (ASX), GENERA BIOSYSTEMS LIMITED (ASX), ALCHEMIA LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.490
+3.62 %
10 Days -+0.280
+2.04 %
20 Days -+0.230
+1.67 %
Medium Term Return 3 Months --1.420
-9.19 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 12.000 - 18.750 Change From 1 Year Low +2.030 % Change From 1 Year Low (%) +16.92
Change From 1 Year High -4.720 % Change From 1 Year High (%) -25.17
2 Years Range 12.000 - 18.750 Change From 2 Years Low +2.030 % Change From 2 Years Low (%) +16.92
Change From 2 Years High -4.720 % Change From 2 Years High (%) -25.17
5 Years Range 12.000 - 18.750 Change From 5 Years Low +2.030 % Change From 5 Years Low (%) +16.92
Change From 5 Years High -4.720 % Change From 5 Years High (%) -25.17
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.

Historical Price Data

Date Open High Low Close Volume VWAP
19 Jul 2019 14.130 14.320 13.920 14.030 28,377 -
18 Jul 2019 14.400 14.579 14.030 14.110 23,092 -
17 Jul 2019 14.190 14.580 14.045 14.370 71,899 -
16 Jul 2019 13.780 14.680 13.750 14.200 85,223 -
15 Jul 2019 13.650 13.880 13.490 13.750 116,000 -
12 Jul 2019 13.950 14.040 13.505 13.540 63,903 -
11 Jul 2019 13.890 14.040 13.520 13.950 139,642 -
10 Jul 2019 13.750 14.040 13.550 13.930 144,583 -
09 Jul 2019 13.530 14.070 13.335 13.690 68,436 -
08 Jul 2019 13.860 13.860 13.420 13.620 42,210 -
05 Jul 2019 13.890 14.379 13.720 13.750 95,197 -
03 Jul 2019 14.460 14.460 13.900 13.960 53,336 -
02 Jul 2019 14.980 14.980 13.940 14.390 59,884 -
01 Jul 2019 15.000 15.000 14.350 14.470 74,588 -
28 Jun 2019 14.750 15.180 14.300 14.640 911,961 -
27 Jun 2019 14.850 14.990 14.185 14.640 65,666 -
26 Jun 2019 14.510 15.156 14.455 14.880 36,328 -
25 Jun 2019 14.180 15.240 13.835 14.420 155,909 -
24 Jun 2019 13.910 14.080 13.330 13.850 101,052 -
21 Jun 2019 13.870 14.280 13.635 13.800 262,279 -
20 Jun 2019 13.790 14.000 13.540 13.900 95,774 -
19 Jun 2019 13.710 14.145 13.540 13.750 143,224 -
Summary
Current 2 Weeks
(08 Jul 2019 to 19 Jul 2019)
13.860 14.680 13.335 14.030 783,365 -
Previous 2 Weeks
(21 Jun 2019 to 05 Jul 2019)
13.870 14.680 13.335 13.750 1,816,200 -
4 Weeks from
(23 May 2019 to 20 Jun 2019)
14.910 15.250 13.335 13.900 1,395,780 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.